Substance / Medication

Mycophenolate sodium

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Graft versus host disease

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?

Gardiner Kyle M, Tett Susan E, Staatz Christine E · Drugs R D · 2018

PMID: 30426342Meta-AnalysisFull text (PMC)

Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus.

Doukaki Spyridoula, Platamone Andrea, Alaimo Roberta et al. · J Dermatolog Treat · 2015

PMID: 24521072Meta-Analysis

Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients.

Budde Klemens, Tedesco-Silva Helio, Arns Wolfgang et al. · Transplantation · 2011

PMID: 21694664Meta-Analysis

Pharmacokinetics and Bioequivalence of Mycophenolate Sodium Enteric-Coated Tablets Under Fasting and Fed Conditions: A Single-Dose, Open-Label, Four-Period Replicated Crossover Study in Healthy Chinese Male Subjects.

Zhang Peiwen, Li Mupeng, Jiang Hao et al. · Drug Des Devel Ther · 2025

PMID: 40959737RCTFull text (PMC)

Bioequivalue of two mycophenolate sodium enteric-coated tablets and the drug monitoring based on limited sampling strategy: A single-center, randomized, open-label, three-period, reference-replicated, crossover study.

Xu Guangxun, Wang Zhendi, Yan Tianzhong et al. · Transpl Immunol · 2023

PMID: 37652363RCT

Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN).

Ranganathan Dwarakanathan, Abdul-Aziz Mohd H, John George T et al. · Ther Drug Monit · 2019

PMID: 31219949RCTFull text (PMC)

Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.

Ferreira Alexandra Nicolau, Felipe Claudia Rosso, Cristelli Marina et al. · Transpl Int · 2019

PMID: 31278785RCT

Limited Sampling Strategy for Mycophenolic Acid in Chinese Kidney Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus During the Early Posttransplantation Phase.

Yao Xi, Huang Hongfeng, Wei Chunchun et al. · Ther Drug Monit · 2015

PMID: 25565669RCT

Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.

Feng J J, Zhang L W, Zhao P et al. · Int J Clin Pract Suppl · 2015

PMID: 26176848RCT

A single-centre, open-label, prospective study of an initially short-term intensified dosing regimen of enteric-coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live-donor kidney transplant recipients.

Cai L, Zeng F, Liu B et al. · Int J Clin Pract Suppl · 2014

PMID: 24673716RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Mycophenolate sodium (substance)
SNOMED CT: 426216009
UMLS CUI: C1337395

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.